title: Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain.
abstract: BACKGROUND
  Schizophrenia is a severe, persistent, and fairly common mental illness. Haloperidol is widely used and is effective against the symptoms of psychosis seen in schizophrenia. Chronic oral haloperidol administration decreased the number of astrocytes in the parietal cortex of macaque monkeys (Konopaske et al., Biol Psych 63:759-765, 2008). Since astrocytes play a key role in glutamate metabolism, chronic haloperidol administration was hypothesized to modulate astrocyte metabolic function and glutamate homeostasis.
  
  
  OBJECTIVE
  This study investigated the effects of chronic haloperidol administration on astrocyte metabolic activity and glutamate, glutamine, and GABA homeostasis.
  
  
  METHODS
  We used ex vivo ¹³C magnetic resonance spectroscopy along with high-performance liquid chromatography after [1-¹³C]glucose and [1,2-¹³C]acetate administration to analyze forebrain tissue from rats administered oral haloperidol for 1 or 6 months.
  
  
  RESULTS
  Administration of haloperidol for 1 month produced no changes in ¹³C labeling of glutamate, glutamine, or GABA, or in their total levels. However, a 6-month haloperidol administration increased ¹³C labeling of glutamine by [1,2-¹³C]acetate. Moreover, total GABA levels were also increased. Haloperidol administration also increased the acetate/glucose utilization ratio for glutamine in the 6-month cohort.
  
  
  CONCLUSIONS
  Chronic haloperidol administration in rats appears to increase forebrain GABA production along with astrocyte metabolic activity. Studies exploring these processes in subjects with schizophrenia should take into account the potential confounding effects of antipsychotic medication treatment.
authors: Department of Psychiatry, Harvard Medical School, Boston, MA, USA, gkonopaske@mclean.harvard.edu.
authors: Glenn T
authors: GT
authors: Konopaske
authors: Nicolas R
authors: NR
authors: Bolo
authors: Alo C
authors: AC
authors: Basu
authors: Perry F
authors: PF
authors: Renshaw
authors: Joseph T
authors: JT
authors: Coyle
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001253:Astrocytes / Q000187:drug effects* / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D005973:Glutamine / Q000378:metabolism; D006220:Haloperidol / Q000008:administration & dosage / Q000494:pharmacology*; D006706:Homeostasis; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D016548:Prosencephalon / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D005973:Glutamine; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D005947:Glucose; D006220:Haloperidol
references: Neuropsychopharmacology. 2006 Sep;31(9):1880-7
references: 16395297
references: NMR Biomed. 2003 Oct-Nov;16(6-7):424-9
references: 14679504
references: Arch Gen Psychiatry. 2001 Feb;58(2):148-57
references: 11177116
references: Neuropsychopharmacology. 1996 Feb;14(2):87-96
references: 8822531
references: J Pharmacol Exp Ther. 1999 Feb;288(2):774-81
references: 9918588
references: Cereb Cortex. 1994 Jan-Feb;4(1):69-77
references: 8180492
references: J Neurosci Res. 2007 Nov 15;85(15):3347-58
references: 17847118
references: Brain Res Mol Brain Res. 1994 May;23(3):204-12
references: 8057777
references: Clinics (Sao Paulo). 2010;65(9):885-94
references: 21049217
references: Biol Psychiatry. 2010 Oct 1;68(7):667-70
references: 20598290
references: Neurochem Int. 2004 Sep;45(4):521-7
references: 15186918
references: Eur J Neurosci. 2003 Jul;18(2):391-402
references: 12887421
references: J Neurochem. 2010 Oct;115(2):483-92
references: 20698931
references: J Neural Transm (Vienna). 1997;104(1):97-104
references: 9085197
references: J Neurosci. 2001 May 15;21(10):3628-38
references: 11331392
references: Arch Gen Psychiatry. 2002 Nov;59(11):1002-10
references: 12418933
references: J Physiol. 2001 Jun 1;533(Pt 2):479-92
references: 11389206
references: J Neurosci. 1994 Jul;14(7):4159-66
references: 7913120
references: J Neurosci. 1998 Jul 15;18(14):5225-33
references: 9651205
references: Synapse. 1994 May;17(1):26-35
references: 8042144
references: Neurochem Int. 2006 May-Jun;48(6-7):498-507
references: 16542760
references: Schizophr Res. 1997 Dec 19;28(2-3):111-25
references: 9468347
references: Brain Res. 1997 Jan 23;746(1-2):239-55
references: 9037503
references: J Biol Chem. 1990 Aug 5;265(22):12916-26
references: 1973931
references: Trends Neurosci. 2004 Dec;27(12):735-43
references: 15541514
references: Eur J Pharmacol. 1996 Aug 1;309(1):25-31
references: 8864689
references: Am J Psychiatry. 2002 Nov;159(11):1944-6
references: 12411236
references: J Clin Psychiatry. 1994 Sep;55 Suppl B:8-14
references: 7961581
references: J Biol Chem. 2010 Mar 19;285(12):8905-17
references: 20080963
references: Mol Psychiatry. 1997 Jul;2(4):322-9
references: 9246673
references: Eur J Pharmacol. 1994 Sep 15;269(1):121-5
references: 7828654
references: J Neurosci. 1988 Jul;8(7):2361-70
references: 2907912
references: Life Sci. 2000 Nov 24;68(1):29-39
references: 11132243
references: Exp Brain Res. 1989;77(3):611-20
references: 2572447
references: J Clin Psychiatry. 2001 Apr;62(4):231-8
references: 11379836
references: Neuropsychopharmacology. 2005 Sep;30(9):1649-61
references: 15756305
references: Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1964-9
references: 11172059
references: Neuropsychopharmacology. 2006 Apr;31(4):751-6
references: 16132064
references: Neuropsychopharmacology. 1999 Jan;20(1):92-6
references: 9885788
references: Eur J Pharmacol. 1990 Nov 20;191(1):19-27
references: 1982657
references: Biol Psychiatry. 2008 Apr 15;63(8):759-65
references: 17945195
references: Adv Exp Med Biol. 2012;970:407-29
references: 22351066
references: Neuroscience. 1997 Mar;77(2):419-29
references: 9472401
references: Eur J Pharmacol. 1980 Oct 31;67(4):363-9
references: 7192633
references: Arch Gen Psychiatry. 2011 Feb;68(2):128-37
references: 21300943
references: J Neurochem. 2003 Jun;85(5):1200-7
references: 12753079
references: Behav Brain Res. 2005 Sep 8;163(2):204-11
references: 16009434
references: Exp Brain Res. 1989;74(3):527-34
references: 2468514
references: Arch Gen Psychiatry. 2005 Apr;62(4):361-70
references: 15809403
references: J Cereb Blood Flow Metab. 2007 Feb;27(2):219-49
references: 16835632
references: J Neurochem. 2012 Mar;120(6):1014-25
references: 22299833
references: Int J Neuropsychopharmacol. 2003 Dec;6(4):325-37
references: 14609439
references: Brain Res. 1994 Jan 14;634(1):20-30
references: 7908848
references: Am J Psychiatry. 2005 Dec;162(12):2233-45
references: 16330585
references: Brain Res. 2002 Aug 30;947(2):157-65
references: 12176156
references: Neuroscience. 2000;100(3):507-14
references: 11098113
references: J Neurosci. 1998 Dec 15;18(24):10553-65
references: 9852592
references: Brain Res Mol Brain Res. 1998 Jul 15;58(1-2):231-6
references: 9685656
references: Schizophr Res. 2004 Feb 1;66(2-3):151-7
references: 15061247
references: J Neurosci. 2004 Nov 24;24(47):10652-9
references: 15564581
references: Brain Res. 1979 Feb 2;161(2):303-10
references: 31966
references: Exp Neurol. 1994 May;127(1):62-9
references: 8200438
references: Am J Psychiatry. 2003 Dec;160(12):2231-3
references: 14638596
references: Neuroreport. 1995 Sep 11;6(13):1795-8
references: 8541484
references: Pharmacopsychiatry. 2004 Jul;37(4):171-4
references: 15467974
references: Neurochem Res. 2004 Jan;29(1):209-17
references: 14992280
references: Life Sci. 1978 May 22;22(20):1777-82
references: 672427
references: Eur J Pharmacol. 1994 Oct 3;263(3):269-76
references: 7843264
references: J Biol Chem. 1999 Jan 8;274(2):889-95
references: 9873028